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Abstract
Background: The human PAF (hPAF) complex is part of the RNA polymerase II transcription apparatus and regulates
multiple steps in gene expression. Further, the yeast homolog of hPaf1 has a role in regulating the expression of a subset of
genes involved in the cell-cycle. We therefore investigated the role of hPaf1 during progression of the cell-cycle.
Methodology/Findings: Herein, we report that the expression of hPaf1, a subunit of the hPAF complex, increases with cellcycle progression and is regulated in a cell-cycle dependant manner. hPaf1 specifically regulates a subclass of genes directly
implicated in cell-cycle progression during G1/S, S/G2, and G2/M. In prophase, hPaf1 aligns in filament-like structures,
whereas in metaphase it is present within the pole forming a crown-like structure, surrounding the centrosomes. Moreover,
hPaf1 is degraded during the metaphase to anaphase transition. In the nucleus, hPaf1 regulates the expression of cyclins A1,
A2, D1, E1, B1, and Cdk1. In addition, expression of hPaf1 delays DNA replication but favors the G2/M transition, in part
through microtubule assembly and mitotic spindle formation.
Conclusion/Significance: Our results identify hPaf1 and the hPAF complex as key regulators of cell-cycle progression.
Mutation or loss of stoichiometry of at least one of the members may potentially lead to cancer development.
Citation: Moniaux N, Nemos C, Deb S, Zhu B, Dornreiter I, et al. (2009) The Human RNA Polymerase II-Associated Factor 1 (hPaf1): A New Regulator of Cell-Cycle
Progression. PLoS ONE 4(9): e7077. doi:10.1371/journal.pone.0007077
Editor: Syed A. Aziz, Health Canada, Canada
Received July 22, 2009; Accepted August 19, 2009; Published September 22, 2009
Copyright: ß 2009 Moniaux et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Institutes of Health #P50 CA72712 and the Peter Kiewit Foundation. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sbatra@unmc.edu
. These authors contributed equally to this work.

tiated cell line, CD11 [13]. Others identified the hPaf1 protein
through co-purification with the parafibromin tumor suppressor
protein, the human homologue of the yeast Cdc73 [4,14]. The
hCdc73 protein is the product of the HRPT2 gene, a tumor
suppressor involved in the hyperparathyroidism-jaw tumor
syndrome (HPT-JT) [15,16]. Several mutated forms of hCdc73
lack the ability to interact with other members of the hPAF
complex. Interestingly, among the five members forming the yeast
complex, only hCdc73, hPaf1, hCtr9, and hLeo1 were found as
subunits of the human complex. Rtf1, present in the yeast
complex, is not purified with the hPAF complex [4,11]. Human
PAF complex interacts with RNAPII and with a histone lysine
methyl transferase (HKMTase) [4]. Woodard et al. showed that
wild-type hCdc73 inhibited cyclin D1 expression, but not the
mutated form of hCdc73 (parafibromin) [17]. In addition, Zhu et
al [11] recently reported that the hPAF complex shares a novel
higher eukaryotic subunit hSki8, common with the human SKI
(hSKI) complex, whose down regulation results in a reduction of
the cellular levels of other hPAF subunits.
In the present study, the role of hPaf1 was investigated during
progression of the cell-cycle based on two sets of observations. First,
three reports suggested a role for the yeast homolog of Paf1 in

Introduction
The RNA polymerase II-associated factor (PAF) complex is a
mediator of histone ubiquitinylation and methylation during the
transcription process in yeast [1,2], plants [3], and mammals [4]. The
yeast Paf1 (yPaf1) complex binds to RNA polymerase II (RNAPII),
coordinating co-transcriptional histone modifications such as histone
H2B mono-ubiquitinylation and histone H3-Lys4, -Lys79 methylation and participates in transcription initiation and elongation [1,5].
The transcriptional process is predominantly mediated by the
activity of RNA polymerase II (RNAPII). As eukaryotic RNAPII
cannot bind directly to DNA, the initiation of transcription
depends on promoter recognition by general transcription factors
(GTFs) [6,7]. PAF complex is one of these factors [for review,
[8,9]]. The PAF complex directly interacts with RNA polymerase
II and regulates multiple steps during gene expression [10,11]
including transcription [1,2,5], elongation [12], mRNA stability,
RNA quality control [11], and RNA export to the cytoplasm
[11,12]. The first cDNA encoding a subunit of the hPAF complex,
hPaf1 (AJ401156), was identified in our laboratory as a differentially expressed mRNA between the poorly differentiated
human pancreatic tumor cell line, Panc1, and the well-differenPLoS ONE | www.plosone.org
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regulating the expression of a subset of genes involved in the cell-cycle
[18,19]. Second, we observed that asynchronously growing cells
undergoing mitosis do not express hPaf1 along with other subunits.
Here, we show that the expression of hPaf1 is temporally regulated
during the cell-cycle, and it is a key regulator of cyclin expression.

confocal immunofluorescence microscopy, all cells undergoing
mitosis showed a weak to no expression (Fig. 1A). Asynchronous
cell cultures of Panc1 were further evaluated by staining with
FITC conjugated anti-hPaf1 antibody, counterstaining with
propidium iodide, and flow cytometric analysis of hPaf1
expression during different phases of the cell cycle (Fig. 1B).
Twenty thousand cells per experiment were sorted in function of
the cell cycle phase (G1, S, and G2) and each cell subpopulation
further examined for hPaf1 expression. The relative fluorescence
intensities were of 69.8, 85.6, and 133.8 for the cells in G1, S, and
G2 phases, respectively. These data suggest that hPaf1 expression

Results
The expression of hPaf1 is regulated during cell cycle
When an asynchronously growing human pancreatic cancer
cell, Panc1, population was observed for hPaf1 expression by

Figure 1. hPaf1 is differentially expressed during the cell cycle. A) The sub-cellular localization of hPaf1 was determined by confocal analysis
of a population of asynchronously growing Panc1 cells that were labeled with FITC-conjugated anti-hPaf1 antibody (green) and counterstained with
propidium iodide (red). hPaf1 was detected in the nucleus of the cells, but was absent from the heterochromatin and the nucleoli. hPaf1 was not
detected in cells going through mitosis (black arrow). B). The FITC-labeled hPaf1 protein was quantified for each phase of the cell cycle. The mean of
fluorescence detected was of 69.79, 85.64, and 133.77 for the cells in the G1-, S- and G2-phases, respectively.
doi:10.1371/journal.pone.0007077.g001
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analyzed for hPaf1 expression/localization and compared with
CD18/HPAF, MCF7, and human fibroblast cells. As depicted in
Fig. 3D1, hPaf1 staining was detected for the cells in the
metaphase. hPaf1 was concentrated at both cellular poles
(Fig. 3D1, black arrows). Similar staining was observed for the
CD18/HPAF (Fig. 3D2), MCF7, and human fibroblast (Fig. 3D6)
cells. hPaf1 was detected in prophase showing a filament-like
staining (Fig. 3D3), concentrated at the cellular poles in the
metaphase (Fig. 3D2 and 3D6), for human fibroblast, MCF7, or
CD18/HPAF cells. Z-sections of cells in the metaphase revealed
that hPaf1 was forming a crown surrounding both centrosomes
(Fig. 3D4, 3D5, and 3D6). The peri-centrosomal localization of
hPaf1 was confirmed by tubulin/hPaf1 co-staining and confocal
microscopy (Fig. 3DE). No staining was detected for any of the
cells at anaphase or telophase. Although hPaf1 level of expression
is 30-fold lower in the CD18/HPAF, and human fibroblast when
compared with the Panc1 cells, hPaf1 concentration surrounding
the centrosome was more intense in these two cell lines. This result
raised the possibility that change in the stoichiometry of the hPAF
complex following gene amplification or gene expression deregulation influenced the subcellular localization of hPAF complex,
therefore modifying its function.
The aforementioned results suggested that hPaf1 is degraded at
the transition from metaphase to telophase. To validate this
hypothesis, protein lysates from cells at T0, T+8, N0, and shake-off
(SO) conditions were incubated with rabbit polyclonal antibody
against ubiquitin. Anti-ubiquitin immunoprecipitates were subjected to immunoblot analysis and associated hPaf1 was visualized
using anti-hPaf1 antibody. An anti-hPaf1 reactive band with a
molecular weight of 80 kDa was detected at very low levels at T0,
but significant quantities were observed at T+8 (Fig. 3B). In
contrast, hPaf1 was not detected at N0 or S0. Because hPaf1
pooled down using anti-ubiquitin antibody presented the same
molecular weight as that in the input control, we concluded that
hPaf1 is not directly ubiquitinylated, but associated with
ubiquitinylated proteins. This hypothesis was validated by
performing reverse immunoprecipitation. Anti-hPaf1 immunoprecipitates were subjected to immunoblot analysis and associated
ubiquitinylated proteins were visualized using anti-ubiquitin
antibody. No band was detected either at T0 or T+8 (Fig. 3B,
lower panel). As control, the membrane was stripped and probed
using the mouse monoclonal antibody, anti-hPaf1 (Fig. 3B, lower
panel). To measure if hPaf1 is sensitive to proteasome activity,
cytoplasmic protein lysates from synchronously growing Panc1
cells (at T+10 h and T+12 h to overlap the transition from G2 to
M) were treated for 12 hours with the proteasome inhibitor
MG132, then immunoprecipitated with the anti-ubiquitin antibody. Ethanol treated cells were used as negative control. There
was a significant increase in the steady-state level of hPaf1
following MG132 treatment as compared to the ethanol control
(Fig. 3C). Therefore, even if not directly ubiquitinylated, hPaf1
may be degraded by a mechanism dependent on the proteasome.

increases with the cell-cycle progression and that the expression of
hPaf1 is regulated in a cell-cycle dependent manner.
We further examined this hypothesis by monitoring hPaf1
expression in a synchronously growing population of Panc1 cells.
Panc1 cells were arrested at the G1/S boundary by a double
thymidine block. The cells were then released in normal medium
containing serum (time 0 = T0) and analyzed every 2 hours for
24 hours by flow cytometry (after propidium iodide staining),
confocal microscopy, and Western blotting of cytoplasmic and
nuclear cell fractions. Results from flow cytometry showed that 80%
of the cell population was in the G1/S phase just before release
(Fig. 2A). The cells progressed into the cell cycle synchronously to
reach a peak of mitosis after 10 to 12 hours(data not shown). The
rates of cells with higher ploidies were noticeable by flow cytometry
(reported to be of 8.5% for the Panc1 cell line [20]).
Immunofluorescence analysis showed the presence of hPaf1 in
nuclei but not in the perinuclear heterochromatin or nucleoli
(Fig. 2B). After 10 to 12 hours, the majority of cells entered
mitosis. Interestingly, upon entry into mitosis, levels of hPaf1
dropped significantly to trace amounts during prophase. Western
blot analysis confirmed these results. A single band of 80 kDa was
detected in the nuclear fraction, while two bands of 60 and 80 kDa
were observed in cytoplasmic extracts (Fig. 2C). The 60 kDa band
was not detected in the cytoplasmic fraction of asynchronously
growing cells. Both 60 and 80 kDa cytoplasmic bands increased
from G1 to G2 with a detectable increase 2 hours after release,
and a maximal increase after 8 h. Levels of hPaf1 dropped at
12 hours(mitosis), and re-appeared after 17 hours, when cells were
back in the G1 phase. The nuclear band of 80 kDa presented a
similar profile but with a detectable increase after 4 hours and a
maximum at 12 h. The deduced molecular weight of hPaf1 is
59.9 kDa [13]. Therefore, our results suggest that the 60 kDa
protein detected represents the hPaf1 precursor, which rapidly
processes into an 80 kDa mature protein and is then transported
to the nucleus and accumulates until the late G2 phase.

hPaf1 is degraded during mitosis
To precisely monitor the status of hPaf1 expression during
mitosis, we compared ten different fields of confocal microscopy
for Panc1 cells in T+12 (double thymidine block followed by
12 hours of release) and N0 (thymidine/nocodazole block) that
synchronized the cells in late G2/early mitosis (checked by flow
cytometry). Representative pictures of T+12 and N0 are depicted
in Fig. 3A. Mitotic cells in N0 showed accumulation of hPaf1 in
the cytoplasm and strong inter-chromatin labeling (black arrow).
The hPaf1 protein appeared to concentrate between the
condensed chromatin in metaphase. In comparison, cells in
T+12 were slightly positive for cytoplasmic hPaf1, and no hPaf1
protein was observed within the condensed chromatin. As
nocodazole is a microtubule-interfering agent that inhibits mitotic
spindle formation, these results suggest that hPaf1 is shuttled or
degraded at mitosis via tubulin filaments.
Since hPaf1 protein is overexpressed 30-fold in the Panc1 cells
by amplification of its chromosomal locus [13], we evaluated its
expression and localization in three other cell lines in which the
gene is not amplified. CD18/HPAF (pancreatic cancer), MCF7
(breast cancer), and normal human fibroblast cell lines were
arrested by double thymidine block at the G1/S boundary and
released for 12 hours to reach a peak at mitosis. Analysis of hPaf1
expression during cell cycle progression was similar to that seen
with Panc1, but at lower overall levels. Cells in mitosis were
analyzed by confocal microscopy. The setting of the confocal was
performed on the CD18/HPAF cells expressing the lowest level of
hPaf1. Using these confocal parameters, the Panc1 cells were rePLoS ONE | www.plosone.org

hPaf1 modulates cell-cycle progression
The oscillatory expression pattern of hPaf1 during the cell-cycle
progression lead us to hypothesize that hPaf1 is a key regulator
of the cell-cycle. To identify its specific functionality during cell
division, we first monitored hPaf1 influence on cell-cycle
progression. For this purpose, hPaf1 was transiently invalidated
by siRNA technology in synchronized Panc1 and human
fibroblast cell populations. Both Panc1 and normal human
fibroblast cells were arrested at the G1/S boundary by a double
thymidine block. Flow cytometric analysis indicated that upto 90%
and 60% of the Panc1 and fibroblast cells respectively were
3
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Figure 2. Localization of hPaf1 during the cell cycle in Panc1 cells. hPaf1 expression was monitored in a synchronously growing population
of Panc1 cells. Panc1 cells were arrested at the G1/S boundary by double thymidine block, then released in normal medium containing serum (time
0 = T0) and analyzed every 2 h for 24 h by flow cytometry (after propidium iodide staining), confocal microscopy, and Western blotting of
cytoplasmic and nuclear cell fractions. A) Eighty percent of the cells were blocked at the G1/S boundary. After release, the cells progressed into the
cell cycle synchronously to reach a peak of mitosis after 10–12 h. Representative fields from the confocal analysis are presented in B). The cells were
grown at low density on cover slips for 24 h, and arrested at the G1/S boundary by double thymidine incorporation. The acetone/methanol (1:1)-fixed
Panc1 cells were labeled using a FITC-conjugated anti-hPaf1 monoclonal antibody and counterstained by propidium iodide. The amount of
fluorescence detected for the cells in T+12 (G2/M) was twice the level detected in T0 (G1/S). Up to 10 fields were monitored for each phase of the cell
cycle. Cells in the prophase, metaphase, anaphase, and telophase showed very low to no expression of hPaf1. C) Nuclear and cytoplasmic protein
extracts were prepared every 2 h and analyzed by immunoblotting using anti-hPaf1 and anti-hLeo1 antibodies. The JLA-20 antibody recognizing b
actin was used as a loading control.
doi:10.1371/journal.pone.0007077.g002
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Figure 3. hPaf1 is ubiquitinylated and degraded at the metaphase/anaphase transition. Panc1 cells were grown at low density on cover
slips for 24 h, and arrested at G1/S (T0) and G2/M (N0) boundaries by double thymidine and thymidine/nocodazole blocks, respectively. Acetone/
methanol (1:1)-fixed Panc1 cells were labeled using a FITC-conjugated anti-hPaf1 monoclonal antibody and counterstained by propidium iodide. Up
to 10 fields were observed by confocal microscopy for cells after 12 h of double thymidine treatment release (T+12) and compared with 10 fields of
thymidine/nocodazole treated cells just before release (N0). Representative pictures are presented in A). The black arrows indicate the interchromatine accumulation of hPaf1 in the prophase for the cells in N0; accumulation was not detected at T+12. B) Proteins from nuclear extracts
performed at T0, T+8, N0, and S0 (shake off cells in N0) were immunoprecipitated using the rabbit polyclonal antibody anti-ubiquitin (Calbiochem),
and immunoblotted with anti-hPaf1 antibody. An aliquot of the nuclear protein extracts was loaded as a control for hPaf1 expression (input), and
immunoprecipitation was carried out using an isotype IgG control antibody as a negative control. C) hPaf1 degradation by the proteasome was
confirmed using the proteasome inhibitor MG132. After double thymidine block, the cells were released either in ethanol control or MG132 (20 mM)
for 12 h. Protein lysates were imunoprecipitated using the rabbit polyclonal antibody anti-ubiquitin (Calbiochem) and immunoblotted with antihPaf1 antibody. D) Panc1, CD18/HPAF, and human fibroblast cells were arrested at the G1/S boundary and released for 12 h to reach a maximum of
mitosis. The cells were analyzed for hPaf1 expression and sub cellular localization by confocal. In the prophase, hPaf1 was found aligned on filamentlike structures (D3) to be concentrated at the pole in the metaphase (D1, D2: black arrow). The Z-section (D4, D5, and D6) revealed that in the
metaphase, hPaf1 formed a crown at both poles of the cells, potentially surrounding the centrosomes (white arrow). E) CD18/HPAF cells were
arrested at the G1/S boundary and released for 12 h to reach a maximum of mitosis. The cells were analyzed for hPaf1 and tubulin expression and
subcellular localization by confocal. In metaphase, hPaf1 co-localized with tubulin, confirming the centrosomal localization of hPaf1.
doi:10.1371/journal.pone.0007077.g003
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the cell population in G1/S and 63.14% for the cells in G2/M.
The same samples were used for the dropping-PCR. As compared
to the control, knockdown of hPaf1 resulted in a reduction of 35%,
36% and 27% in G1/S for cyclins E1, B1, and D1, respectively
(Fig. 5B, 5C). In G2/M, knockdown of hPaf1 inhibited expression
only for cyclin B1 with a reduction of 29% (Fig. 5B, 5C). The level
of amplification of cyclin A2 and A1 were too low to precisely
measure variation in expression. Altogether, these results suggest
that the hPaf1/hPAF complex contributes to regulation of cellcycle associated cyclin transcription. Regarding cyclin D1, even
though there was no observed interaction between hPaf1 and the
cyclin D1 promoter, a 27% reduction in cyclin D1 expression was
noted in G1/S, but not in G2/M. This suggests that hPaf1
influences cyclin D1 regulation through another mechanism.
Direct effects were observed for cyclins E1 and B1, indicating that
hPaf1 positively stimulates transactivation of cyclin E1 in G1/S
and cyclin B1 in G1/S and G2/M. Therefore, the hPaf1/hPAF
complex contributes to regulation of cell-cycle progression, and
may be a key component of the cell-cycle ‘‘circadian rhythm.’’

arrested in the G1 phase before release. The cells were then
released in normal medium containing serum (time 0 = T0) and
analyzed every 2 hours for 24 hours by flow cytometry for BrdU
incorporation and propidium iodide staining (Fig. 4). Invalidation
of hPaf1 expression in the fibroblast (Fig. 4C) and Panc1 (Fig. 5D)
cells was confirmed by real-time PCR. Both Panc1 and human
fibroblast cells knocked down for hPaf1 enter S-phase 2 hours in
advance on an average when compared to the scramble control
(measured by BrdU uptake and propidium iodide). In addition, the
cells presented a longer G2-phase when hPaf1 expression was
invalidated (Fig. 6B). Altogether, our results show that hPaf1
delays the onset of DNA replication by 2 hours as depicted by
BrdU incorporation, but favors the G2/M transition.

The hPaf1/hPAF complex is a key regulator of cyclin
transcription initiation
At this point, one important question was whether hPaf1 was
acting alone or in association with the other members of the hPAF
complex. To this aim, we examined the pattern of expression of
another member of the hPAF complex, hLeo1, through cell-cycle
progression. For this purpose, the western blot membranes from
Fig. 2C were stripped and reprobed with an anti-human Leo1
antibody. Like hPaf1, hLeo1 expression increased in S-phase and
reached a maximum level of expression in G2. In mitosis, the
hLeo1 level appeared comparable to its level in G1. The
oscillatory pattern of expression of hLeo1 during cell-cycle
progression is comparable to hPaf1 expression.
Given its role in the transcription process and its oscillatory
expression pattern during cell-cycle progression, we hypothesized
that hPaf1 contributes to the initiation and prolongation of cyclin
expression. Binding of hPaf1 at promoter sequences of cyclin genes
was investigated by chromatin immunoprecipitation using Panc1
cells that were synchronized by double thymidine or thymidine/
nocodazole block. DNA and proteins were cross-linked at T0 and
N0 corresponding to G1/S and early mitosis, respectively. Crosslinked hPaf1-DNA complexes, immunoprecipitated with antihPaf1 antibody, were analyzed (after a cross-linking reversion) for
associated DNA by PCR using specific primers for the promoters
of cyclins D1/A1/A2/B1, and Cdk1. The assay was also
performed for the promoter of cyclin E1; however, multiple sets
of primers in the promoter region were unsuccessful in the control
assay for total DNA. The association of hPaf1 was specifically
detected for the promoters of cyclin A1 in the G1/S phase, cyclin
B1 in the G2/M phase, and cyclin A2 and Cdk1 at the G1/S and
G2/M phases (Fig. 5A). No association was detected with the
promoter of cyclin D1 at any stage of the cell cycle (Fig. 5A).
To monitor the effect of hPaf1 on the specific promoter activity
of the aforementioned genes, a semi-quantitative dropping-RTPCR was performed. Optimal PCR conditions required exponential amplification, which was determined by preliminary rangefinding experiments. Total amplification of each multiplex
reaction was kept below saturation levels to allow the amplifier
to remain within the exponential range of the amplification curve
and to provide semi-quantitative data. Dropping-RT-PCR was
previously used and reported to monitor cyclin expression [21,22].
The dropping-RT-PCR was carried out on RNAs extracted from
cells that were synchronized by double thymidine block at T0
(G1/S) and T+8 (G2/M). Both parental and siRNA-hPaf1
knocked down Panc1 cells were investigated. Knock down of
hPaf1 expression after siRNA transfection in T0 and T+8 cell
populations was measured by one-step real-time PCR with a
TaqManH probe, following the absolute standard curve method.
Results (ratio of hPaf1 molecules per GAPDH molecules) are
presented in Fig. 5D. Reduction of hPaf1 expression was 32.8% for
PLoS ONE | www.plosone.org

hPaf1 plays a role during the cell-cycle independent of its
role in transcription
Several lines of evidence suggest that hPaf1 possesses biological
activities during the cell-cycle progression independent of its
functions during transcription elongation.
First, if hPaf1 knockdown leads to 35% decrease of cyclin E
expression, it also favors entry of DNA replication. These two
observations seem contradictory as cyclin E is involved in the
transition from G1 to S. We therefore hypothesized that hPaf1
could act in the replication process. The synthesis of the new DNA
strand is the result of the collaborative work between multiple
DNA polymerases: the priming DNA polymerase, a-primase (Pol
a), and the replicative DNA polymerases, pol d and pol e. Since
hPaf1 associates with the RNA polymerase II and that Pol a has a
primase activity, we focused our interest on a putative interaction
between hPaf1 and Pol a. Pol a is a heterotetrameric protein
complex that is involved in DNA replication. The replication
factor consists of the DNA synthesizing DNA polymerase a and
the RNA synthesizing DNA-dependent RNA primase; both
enzymes are required to synthesize the RNA/DNA primers
during the initiation and elongation process of DNA replication.
Proteins immunoprecipitated using both anti-polymerase a
antibodies, SJK132-20 (specific for phosphorylated Pol a) and
HP180-12 (specific for hypophosphorylated Pol a) [23], were
analyzed for association with hPaf1 and hLeo1 by Western blot
analysis. Results show that hPaf1 and hLeo1 co-immunoprecipitated with the phosphorylated and hypophosphorylated forms of
Pol a (Fig. 6A). Interaction of hPaf1 and hLeo1 with Pol a was
detected in G1/S and G2/M. At this point, we do not know the
precise function of hPAF/Pol a interaction; however, as hPAF
complex appears to delay S-phase entry, we hypothesized that
hPAF1 complex/Pol a interaction enables Pol a recruitment at site
of DNA replication, limiting its functionality. To confirm or
invalidate this hypothesis, human fibroblast cells were treated
either with hPaf1 or scramble siRNAs, synchronized at the G1/S
boundary, released for 30, 60, 120, and 280 min, and analyzed by
confocal analysis using the HP180-12 antibody recognizing the
hypophosphorylated Pol a. Hypophosphorylated Pol a localized at
replication initiation sites (Fig. 6B). Two hours after release,
hypophosphorylated Pol a was mainly localized within the
cytoplasm of the cells treated with scramble siRNA, while it
localized at replication sites on chromosomal DNA for the cells
invalidated for hPaf1 expression. Therefore, hPaf1 delays the
loading of hypophosphorylated Pol a at sites of replications.
6
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Figure 4. hPaf1 regulates the cell cycle. A) Panc1 and human normal fibroblast cells were transfected either using a hPaf1 or scramble siRNA,
and synchronized at the G1/S boundary by double thymidine block. The cell cycle progression was measured by propidium iodide staining and BrdU
uptake every 2 h for 24 h. The BrdU was added one hour before each time point. B) Bar diagram summarizing the results of the cell-cycle kinetic for
both human fibroblast and Panc1 cells. FH: fibroblast cells knock down for hPaf1, FSc: fibroblast cells transfected with the scramble siRNA, PH: Panc1
cells knock down for hPaf1, PSc: Panc1 cells transfected with the scramble siRNA. The bars represent the percentage of cells in each phase of the cellcycle measured by propidium iodide, and the lines represent the percentage of BrdU uptake for each time point. C) Suppression of hPaf1 expression
by the fibroblast cells after transfection with siRNA oligonucleotide was measured by one-step real time RT-PCR using a TaqMan probe following the
absolute standard curve method. Standard curves were established using hPaf1 and GAPDH mimics. Sequences and conditions used in this
experiment are available upon request.
doi:10.1371/journal.pone.0007077.g004
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Figure 5. hPaf1 is a key regulator for temporal transcription of cyclins. A) Chromatine immunoprecipitation using hPaf1 anitbody for cyclins
A1, A2, E1, D1, B1, and the Cdk1. An aliquot of the DNA extract before immunoprecipitation was used as a positive control for the PCR amplification.
B) Analysis of cyclins E1, B1, D1, and A2 expression was done by relative competitive dropping-PCR on T0 and T+8 synchronized Panc1 cells. To
measure the effect of hPaf1 expression, hPaf1 was down-regulated using the siRNA technology. C) Values of the dropping-PCR were adjusted for
assay variation by dividing the integrated optical density of cyclins A2, B1, D1, and E1 mRNA by the integrated optical density of GAPDH mRNA. D)
Suppression of hPaf1 expression by the Panc1 cells after transfection with siRNA oligonucleotide was measured on the same RNAs used for the
dropping-PCR by one-step real time RT-PCR using a TaqMan probe following the absolute standard curve method. Standard curves were established
using hPaf1 and GAPDH mimics. Sequences and conditions used in this experiment are available upon request.
doi:10.1371/journal.pone.0007077.g005

human fibroblast cells were transfected either using hPaf1 siRNA
or scramble control, synchronized by double thymidine block and
released for 10 and 12 hours in normal medium. Knockdown of
hPaf1 was followed by confocal microscopy (Fig. 6C). As
aforementioned, transient transfection of hPaf1 siRNA leads to
63% reduction of hPaf1 expression, measured by real time RTPCR. In the current experiment, cells transfected using the
scramble control revealed a strong nuclear staining of hPaf1

Nonetheless, the inter-chromatin accumulation of hPaf1 after
nocodazole treatment reveals a direct association between spindle
formation and hPaf1 subcellular localization. In addition, during
prophase, hPaf1 aligns on tubule-like structures and migrates to
the cellular poles at metaphase forming a crown surrounding the
centrosomes. Its subcellular localization during mitosis lead us to
hypothesize that hPaf1 participates in tubulin polymerization and
spindle formation. To validate this hypothesis, Panc1, MCF7, and
PLoS ONE | www.plosone.org
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Figure 6. hPaf1 during initiation of DNA replication and spindle formation. A) Protein extracts from G1/S (double thymidine arrested: T0)
and G2/M (thymidine/nocodazole arrested: N0) were prepared, and equal amounts of proteins were used for immunoprecipitation using HP180-12
and SJK132-20 mouse monoclonal anti-Polymerase a antibodies. Immunoprecipitates were immunoblotted with anti-hPaf1 and anti-hLeo1
antibodies. An aliquot of the protein extracts at T0 was loaded as the control expression (input). B) Fibroblast cells were arrested at the G1/S
boundary and released for 12 h to reach a maximum of mitosis. The cells were analyzed for Pol a expression and sub cellular localization by confocal
using HP180-12 antibody 2 h after release. At that time frame, cells invalidate for hPaf1 expression presented Pol a loaded to chromosomal DNA
while cytoplasmic for the control cells. C) Invalidation of hPaf1 was evaluated by confocal microscopy. The nuclear localization of hPaf1 stained in
blue using the Cy5 dye was detected for the MCF7 cells transfected by the scramble siRNA, while no staining was detected for the cells transfected
with hPaf1 siRNA. D) Twenty randomly chosen cells in metaphase were observed on each slide by confocal microscopy using a FITC-labelled antitubulin monoclonal antibody (DM1A, Abcam). Representative pictures for MCF7 control and MCF7 invalidated for hPaf1 are presented. Eighty percent
of the cells observed presented defect in tubulin polymerization and spindle formation.
doi:10.1371/journal.pone.0007077.g006

each section. We observed an impairment in tubulin polymerization and spindle formation for 80% of the cells invalidated for
hPaf1 expression. Representative pictures are presented on Fig. 6D
for the MCF7 cells. Z-sections were performed to confirm that the

(Fig. 6C, blue), while no staining was detected for the cells
transfected using hPaf1 siRNA. The cells were further investigated
for tubulin polymerization and spindle formation by confocal
microscopy. Twenty cells in metaphase were randomly chosen on
PLoS ONE | www.plosone.org
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defect observed was not an artifact associated with the field of
observation. Defect in spindle formation may lead to the G2/M
transition delay observed after hPaf1 invalidation.

chromosomal DNA. Increase in cyclin E expression favors loading
of Cdc45 at DNA replication initiation site and promotes DNA
replication. Recently, another laboratory observed similar results
on DNA replication after hPaf1 invalidation. Yart et al. [14]
reported that siRNA-mediated knockdown of parafibromin and
hPaf1 on ansynchronously growing HeLa and U2-OS cell
populations induced entry into S phase, validating our data. This
apparent contradiction among the results points out a multiplicity
of function for hPaf1 during the G1/S transition. On one hand,
hPaf1 acts through cyclin E to initiate DNA replication, but on the
other hand, it acts through an unknown mechanism to delay DNA
replication. As aforementioned, the two newly identified hPaf1
partners, Ski8 and URI, function during DNA replication for
DNA double strand break repair. This leads us to hypothesize that
hPaf1 is involved in DNA repair. In addition, our results show that
hPaf1 interacts with both hypo and phosphorylated forms of the
DNA polymerase-a primase leading to an apparent sequestration
of Pol a within the cytoplasm of the cells. Doing so, hPaf1 might
act as a sensor allowing all proteins required for proper replication
to be actively present at the same time.
In light of the results presented in this article and summarized in
Fig. 7, hPaf1 and/or hPAF complex controls the cell-cycle
progression. Our results suggest a dual functionality for the
members of the hPAF complex. Partial invalidation of hPaf1
promotes the onset of DNA replication, presenting hPaf1 as a
tumor suppressor, while overexpression of hPaf1 presents a
transforming phenotype. A tight temporal and spatial regulation
of the hPAF complex members may be required for proper
functionality, with loss of stoichiometry or mutation of at least one
of the members potentially leading to cancer development.

Discussion
The human homologue of the yeast transcription elongation
factor, Paf1, was recently identified by our laboratory and others
[24]. The role of Paf1 in transcription elongation is now well
established in yeast. hPaf1 is part of the human PAF complex
along with hCdc73 (parafibromin), hCtr9, and hLeo1. Interestingly, this human PAF complex lacks the Rtf1 protein, component
of the yeast core complex. However, two additional subunits were
recently identified as part of the human core complex, hSki8 [25]
and URI [14,26]. Both Ski8 and URI are known for their active
role during RNA synthesis. Ski8 is a member of the SKI complex,
involved, together with the exosome, in the 39-59 mRNA decay
[27]. URI, unconventional prefoldin RPB5 interactor, is a
scaffolding protein involved in TOR-controlled transcription
pathways, controlling the transcription of distinct sets of nutrient
metabolism genes [28]. These results strongly suggest a multifunctional role of the PAF complex during the transcription
process, potentially involved in TOR-controlled transcription
pathway [14], and events downstream of mRNA synthesis such
as mRNA surveillance [11]. Additionally, both Ski8 and URI are
involved in genome integrity, acting during double strand break
repair in meiosis and mitosis [26,29].
Our results present a functional multiplicity for hPaf1 acting as a
key regulator of cell-cycle progression. The first line of evidence is
given by the temporal expression and spatial localization of hPaf1
within the cell-cycle progression. The hPaf1 variation of expression/
localization during the progression of the cell-cycle is similar to the
differential expression pattern of the cyclin proteins, more specifically
cyclin B1. Cyclin B1 controls the entry into mitosis as part of the
maturation (or M-phase)-promoting factor (MPF). Cyclin B1 is
temporally and spatially expressed with an accumulation starting in
late S and a peak at the G2/M transition [30]. Its temporal
accumulation is required for the G2/M transition and its degradation
leads the cells to exit mitosis. Inhibition of hPaf1, using the siRNA
technology, leads to a 29% decrease of cyclin B1 expression and a
delay in the G2/M transition. These two lines of evidences strongly
suggest that hPaf1 regulates the G2/M transition via cyclin B1
expression. However, one question remains unsolved. Why does
hPaf1 align with tubulin filaments during prophase to finally form a
crown surrounding the centrosome at metaphase? Invalidation of
hPaf1 leads to tubulin polymerization and spindle formation defects,
presenting hPaf1 as an active component during mitosis. Human Paf1
differs from its yeast homologue by its carboxyl-terminal domains,
harboring a serine arginine rich and a RCC1 domains [31]. RCC1
stands for regulator of chromosome condensation and is a guaninenucleotide-exchange factor for the small G-protein Ran [32]. Binding
of RCC1 at chromatin generates high concentration of RanGTP on
mitotic chromosome, favoring spindle formation [33]. Other RCC1
domain containing proteins, such as Nercc1, are also known to bind
RanGTP, regulating mitotic progression [34]. In human, hPaf1 may
participate in spindle formation via its RCC1 domain. Further
experiments will need to be performed to confirm this hypothesis.
On the other hand, if hPaf1 knockdown favors entry of DNA
replication, it also leads to 35% decrease in cyclin E expression,
which seems a paradox. Cyclin E is involved in the transition from
G1 to S [35]. Cyclin E is required for the assembly of the
replication initiation complex, specifically for the interaction of
mini-chromosome maintenance protein (MCM) replicative helicase [36] and the Pol a loading factor Cdc45 [37] onto
PLoS ONE | www.plosone.org

Materials and Methods
Materials
The Panc1 and CD18/HPAF cell lines [20], was obtained from
the American Type Culture Collection (ATCC). The human
fibroblast cells were a gift from the Dr. Michel Ouellette (Eppley
cancer Institute, Omaha, NE). For double thymidine cell arrest,
cells were treated with thymidine (Sigma) at 2 mM final
concentration for 18 hours, released in normal medium, and
treated again for 18 hours with a 2 mM final concentration of
thymidine. For the thymidine/nocodazole (Sigma) block, cells
were incubated with thymidine at a 2 mM final concentration for
18 hours, released in normal medium for 10 hours and incubated
with nocodazole at 100 nM final concentration for 15 hours. The
proteasome inhibitor MG132 was purchased from BIOMOL
international. The mouse monoclonal antibody anti-hPaf1 was
produced in our laboratory. The rabbit polyclonal antibody antihLeo1 was provided by Dr. Danny Reinberg (Howard Hughes
Medical Institute, New York, NY). Both mouse monoclonal antipolymerase a antibodies SJK132-20 and HP180-12, were
provided by Dr. Irena Dornreiter (Heinrich-Pette-Institute,
Hamburg, Germany). The rabbit polyclonal anti-ubiquitin
antibody was purchased from Calbiochem and the JLA-20 rabbit
polyclonal anti-actin antibody from the University of Iowa.

Flow cytometry
Confluent cells were detached from the flask with trypsin,
washed in PBS, and fixed in 2 mM glycin [pH 2]/70% ethanol.
Fixed-cells were then washed and resuspended in 1 ml of Telford
reagent (90 mM EDTA, 2.5 mU of RNase A/ml, 50 mg of
propidium iodide/ml, and 0.1% Triton X-100 in PBS). The total
DNA content was analyzed in a FACSCalibur analyzer using
ModFit LT software (Becton Dickinson).
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Figure 7. hPaf1 during cell cycle progression. hPaf1 expression initiates in early G1, increases during the S-phase and reaches a maximum level
in early G2. Synthesized as a 60 kDa protein, hPaf1 translocates as an 80 kDa protein into the nucleus. In the nucleus, hPaf1 directly regulates the
expression of the cyclins A1, A2, D1, E1, B1. In S phase, hPaf1 interacts with the DNA polymerase a-primase complex and delays the onset of DNA
replication. At mitosis, hPaf1 migrates to the cellular pole, forming a crown surrounding the centrosomes. It is then possibly shuttled via tubulin
filaments to be degraded by the proteasome.
doi:10.1371/journal.pone.0007077.g007

cytoplasmic extraction buffer (10 mM Hepes, pH 7.4, 10 mM
KCl, 0.2% NP-40, 0.1 mM EDTA, 10% glycerol, 1.5 mM
MgCl2, 1 mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5 mM
NaF), supplemented with complete protease inhibitor cocktail
[Roche]). Cell disruption was accomplished by several passages
through a 25G needle. Nuclei were collected by centrifugation at
16,000 g, and the supernatant further centrifuged at 16,000 g to
yield the final cytoplasmic extract. Nuclear pellets were incubated
in hypertonic nuclear extraction buffer (20 mM Hepes, [pH 7.6],
420 mM NaCl, 1 mM EDTA, 20% glycerol, 1.5 mM MgCl2,
1 mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5 mM NaF,
supplemented with complete protease inhibitor cocktail [Roche]).
Insoluble materials were precipitated by centrifugation. The
supernatant was collected and used as nuclear extract.

Confocal Microscopy
Cells were plated onto sterile round cover slips (CIR 18-1 Fisher
brand 12-545-10) and grown in 12-well plates. Cells were fixed in
acetone/methanol (1:1; pre-chilled to 220uC) and permeabilized in
0.1% Triton X-100 in PBS. Cells were washed in PBS and incubated
with primary (for 2 hours) and secondary antibodies (for 30 min) at
room temperature. Antibodies were diluted in 5% goat serum.

Preparation of cytoplasmic and nuclear protein extract,
immunoprecipitation, and western blot
The protocol for cytoplasmic and nuclear extract preparation
was adapted from previously published procedures [38,39]. Cells
were allowed to swell on ice for 30 minutes in hypotonic
PLoS ONE | www.plosone.org
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Immunoprecipitation was performed by adding 5 mg of the
appropriate antibodies, and negative controls IgG control to
100 mg of protein extract. The reaction mixture was incubated
overnight on a rotator at 4uC, pulled down with protein G beads,
and washed in TBST. Immuno-complexes were eluted from the
protein G bead by boiling in 6x loading buffer. Immunoprecipitate
proteins or protein extracts were resolved on a 10% SDS gel and
transferred onto polyvinylidene difluoride (PVDF) membranes.
Blocked membranes were reacted with anti-hPaf1 mouse monoclonal antibody at 1 mg/ml in PBS containing 0.05% Tween-20
(PBST) overnight at 4uC. Membranes were then washed six times
(ten minutes each) in PBST and incubated in TBST containing
sheep anti-mouse polyclonal antibody conjugated to horseradish
peroxidase (1:2000 dilution) for one hour at room temperature.
Following six rinses in PBST, ECL reagents (Amersham, USA)
were applied to membranes.

activation step was at 94uC for four minutes, followed by the
denaturation step at 94uC for one minute, primer-annealing step
at 55uC for 30 seconds, extension step at 72uC for one minute, and
the final extension step at 72uC for ten minutes. PCR reaction
products were subjected to electrophoresis using a 2% agarose gel.
Gels were stained using 0.5 mg/ml of ethidium bromide,
illuminated with UV light, photographed using a digital camera,
and analyzed by computerized densitometric scanning of the
images using QuantityOne version 4.1.1 software (Bio-Rad).
Values were adjusted for assay variation by dividing the integrated
optical density of cyclins A2, B1, D1, and E1 mRNA by the
integrated optical density of GAPDH mRNA.

RNA interference
The region of hPaf1 targeted for siRNA was 59-AACAGGUUCGUCCAGUACAAA-39. Synthetic sense and antisense
oligonucleotides (Dharmacon, Lafayette, CO) were annealed in
100 mM potassium acetate, 30 mM HEPES-KOH (pH 7.4),
and 2 mM magnesium acetate for one minute at 90uC and one
hour at 37uC, and frozen. Oligonucleotides were transfected
into cells with TransIT-TKO (Mirus, Madison, WI) in accordance
with the supplier’s recommendations. Cells were treated by double
thymidine incorporation 24 hours after transfection when
required.

ChIP Assay
Panc1 cells were fixed with 1% formaldehyde, washed,
harvested and re-suspended in 200 ml SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-HCl [pH 8.1], 1 mM PMSF, and
1 mg/ml aprotinin). Samples were sonicated and diluted in ChIP
Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, 1 mM PMSF, and
1 mg/ml aprotinin). Immunoprecipitation was performed as
previously described. Chromatin extracts were pulled down with
a protein G bead. The samples were washed extensively and the
cross-links were reversed by incubating the samples at 65uC for
4 hours in 0.3 M NaCl. Immunoprecipitated DNA was amplified
by PCR with specific primers for cyclins A1, A2, E1, D1, B1, and
the Cdk1, loaded on a 2% agarose gel and visualized with
ethidium bromide. All primers used in this study are available
upon request.
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